EGFR and non-small cell lung carcinoma: In MET-positive NSCLC tumors with mutant EGFR that were found resistant to EGFR TKIs, a phase Ib/II study of INC280 in combination with gefitinib reported partial responses in 8/46 (17%) of evaluable patients with high MET status (IHC 3+ and/or MET copy number via FISH ≥5) (NCT01610336).